Document:

CONSULTING AGREEMENT

 

This Consulting Agreement (the "Agreement")
is made and entered into to be effective January 23rd, 2013 (the "Effective Date") by and between Millennium
Medical Devices LLC. (the "Company") located at 400 Garden City Plaza, Suite 440, Garden City, NY 11530 and MedMart (the
“Consultant”) located at 3994 Amboy Road, Staten Island, NY 10308.

 

WHEREAS:

 

		A.	The Consultant has the professional business and industry expertise and experience to assist the
Company;

		B.	The Consultant is offering its services as a consultant to the Company;

		C.	The Company desires to retain the Consultant as an independent consultant and to memorialize the
Consultant's work for the Company by entering into this written Agreement;

		D.	The parties agree that this Agreement reflects the entire understanding and agreements between
the parties hereto and this Agreement shall supersede any and all agreements, written or oral, by and between the parties; and

		E.	This Agreement shall be for a term of 36 months unless otherwise terminated as provided for herein.

		F.	For the duration of this Agreement, Consultant shall give the Company rights of first refusal on
any and all healthcare products identified by Consultant before such products may be offered into the general market place.

 

NOW, THEREFORE, in consideration
of the premises and promises, warranties and representations herein contained, it is agreed as follows:

 

		1.	DUTIES. The Company hereby engages the Consultant and the
Consultant hereby accepts engagement as a consultant. It is understood and agreed, and it is the express intention of the parties
to this Agreement, that the Consultant is an independent contractor, and not an employee or agent of the Company for any purpose
whatsoever. Consultant shall perform all duties and obligations as described on Exhibit A hereto and agrees to be available at
such times as may be scheduled by the Company. It is understood, however, that the Consultant will maintain Consultant's own business
in addition to providing services to the Company. The Consultant agrees to promptly perform all services required of the Consultant
hereunder in an efficient, professional, trustworthy and businesslike manner. A description of the Consultant's services are
attached hereto as Exhibit A and incorporated by reference herein. In such
capacity, Consultant will utilize only materials, reports, financial information or other documentation that is approved in writing
in advance by the Company.

 

		2.	CONSULTING SERVICES & COMPENSATION. The Consultant will be retained as a Consultant
and independent contractor for the Company. For services rendered hereunder, the Consultant shall receive:

 

Each product proposal form presented
by the Consultant and selected and contracted for distribution by the Company will be negotiated and must be fully executed and
added and attached to this Agreement’s Exhibit B.

 

    	1

    	 

    

 

On a product by product basis,
for products properly presented by Consultant and selected and signed off for distribution by Company in Exhibit B, Consultant
can earn up to [*] of GAAP EBITDA in cash commission on all such products and Consultant shall also earn stock based compensation
in the form of either preferred stock, restricted common stock or warrants, which will be determined on product by product basis.
Consultant shall be paid earned compensation on a quarterly basis and such payments shall survive this Agreement.

 

It is further acknowledged by
the Consultant that certain criteria must be met and accepted by the Company for all products proposed. Each product proposed by
the Consultant, on a product by product basis, must meet or exceed the following criteria; have obtained FDA approval, have obtained
Medicare and commercial third-party payor approvals with related proven reimbursement and have initial product inventory along
with product rollout working capital requirements completely and appropriately funded. Each product proposed, as provided for in
Exhibit B, shall specifically state the compensation criteria to be met for that product.

 

Any and all compensation for each
product as described in this Section 2, and on a product by product basis, shall become effective only upon full execution of an
exclusive agreement for distribution of a product with the manufacturer and/or laboratory, a properly submitted and signed Product
Proposal Form, as provided for in Exhibit B, and the complete, appropriate and acceptable funding of all initial required product
inventory, as per product agreement, and working capital requirements for successful product rollout.

 

		3.	CONFIDENTIALITY &
NON-CIRCUMVENT. All knowledge and information of a proprietary and confidential nature relating to the Company which the
Consultant obtains during the Consulting period, from the Company or the Company's employees, agents or consultants shall be for
all purposes regarded and treated as strictly confidential for so long as such information remains proprietary and confidential
and shall be held in trust by the Consultant solely for the Company's benefit and use and shall not be directly or indirectly
disclosed by the Consultant to any person without the prior written consent of the Company, which consent may be withheld
by the Company in its sole discretion. Consultant further agrees that no effort shall be made to circumvent the Company,
this Agreement or the terms thereof in an effort to gain fees, commissions, remuneration, or considerations to the benefit of
Consultant or to exclude the Company of such a benefit. Consultant further hereby agrees to keep completely confidential and to
not disclose the names of any bank, lending institutions, corporations, individuals or groups of individuals, lenders or borrowers,
buyers or sellers, vendors or suppliers, manufacturers, customers or any other third party introduced, located or identified by
the Company or its associates. Such identity shall remain confidential and shall include, but not be limited to, any telephone
numbers, facsimile numbers, postal addresses and email addresses, or any other pertinent information, etc. All of such information
shall also be considered the trade secrets of the Company and shall not be disclosed without the express written consent of the
Company, which consent may be withheld by the Company in its sole discretion.

 

    	2

    	 

    

 

		4.	INDEPENDENT CONTRACTOR STATUS. Consultant understands that
since the Consultant is not an employee of the Company, the Company will not withhold income taxes or pay any employee taxes on
its behalf nor will it receive any fringe benefits. The Consultant shall not have any authority to assume or create any obligations,
express or implied, on behalf of the Company and shall have no authority to represent the Company as agent, employee or in any
other capacity except as herein provided. The Consultant does hereby indemnify and hold harmless the Company from and against any
and all claims, liabilities, demands, losses or expenses incurred by the Company if (1) the
Consultant fails to pay any applicable income and/or employment taxes (including interest or penalties of whatever nature), in
any amount, relating to the Consultant's rendering of consulting services to the Company, including any attorney's fees or costs
to the prevailing party to enforce this indemnity or (2) Consultant takes any action or fails to take any action in accordance
with the companies instructions. The Consultant shall be responsible for obtaining workers’ compensation insurance coverage
and agrees to indemnify, defend and hold the Company harmless of and from any and all claims arising out of any injury, disability
or death of the Consultant.

 

		5.	REPRESENATIONS AND WARRANTS.
For purposes of this Agreement and the Stock, the Consultant represents and warrants as follows:

 

		a.	The Consultant (i) has adequate means of providing for the Consultant's current needs, (ii) is
able to bear the substantial economic risks of an investment in the Shares for an indefinite period, (iii) at the present time,
can afford a complete loss of such investment, and (iv) is an "accredited investor" as defined in the Securities Act
of 1933, as amended.

 

		b.	The Consultant does not have a preexisting personal or business relationship with the Company or
any of its directors or executive officers, or by reason of any business or financial experience or the business or financial experience
of any professional advisors who are unaffiliated with and who are compensated by the Company or any affiliate or selling agent
of the Company, directly or indirectly, could be reasonably assumed to have the capacity to protect the Consultant's interests
in connection with the investment in the Company.

 

		c.	The Consultant is aware that:

 

		i.	The Shares are not transferable under this Agreement and applicable securities laws; and

 

		ii.	The Articles of Incorporation and Bylaws of the Company contain provisions that limit or eliminate
the personal liability of the officers, directors and agents of the Company and indemnify such parties for certain damages relating
to the Company, including damages in connection with the Shares and the good-faith management and operation of the Company.

 

		iii.	Any and all accepted products by the Company for sales/distribution are on best efforts basis.

 

    	3

    	 

    

 

		d.	The Consultant acknowledges that the shares, which are exchangeable for securities are not currently
registered under any registration statement with the Securities and Exchange Commission (SEC) but will have piggy back registration
rights on any and all registration statements filed with Company securities. This provision extends for 2 years beyond termination
of this agreement.

 

		e.	The Consultant has not been furnished any offering literature and has not been otherwise solicited
by the Company.

 

		f.	The Company and its officers, directors and agents have answered all inquiries that the Consultant
has made of them concerning the Company or any other matters relating to the formation, operation and proposed operation of the
Company and the offering and sale of the Shares.

 

		g.	The Consultant, if a corporation, partnership, trust or other entity, is duly organized and in
good standing in the state or country of its incorporation and is authorized and otherwise duly qualified to purchase and hold
the Shares. Such entity has its principal place for business as set forth on the signature page hereof and has not been formed
for the specific purpose of acquiring the Shares unless all of its equity owners qualify as accredited individual investors.

 

		h.	All information that the Consultant has provided to the Company concerning the Consultant, the
Consultant's financial position and the Consultant's knowledge of financial and business matters, or, in the case of a corporation,
partnership, trust or other entity, the knowledge of financial and business matters of the person making the investment decision
on behalf of such entity, including all information contained herein, is correct and complete as of the date set forth at the end
hereof and may be relied upon, and if there should be any material adverse change in such information prior to this subscription
being accepted, the Consultant will immediately provide the Company with such information.

 

		i.	The Consultant certifies, under penalties of perjury (i) that the taxpayer identification number
shown on the signature page of this Consulting Agreement is true, correct and complete, and (ii) that the Consultant is not subject
to backup withholding as a result of a failure to report all interest or dividends, or because the Internal Revenue Service has
notified the Consultant that the Consultant is no longer subject to backup withholding.

 

		j.	In rendering the services hereunder and in connection with the Shares,
the Consultant agrees to comply with all applicable federal and state securities laws, the rules and regulations thereunder, the
rules and regulations of any exchange or quotation service on which the Company's securities are listed and the rules and regulations
of the National Association of Securities Dealers, Inc.

 

    	4

    	 

    

 

		6.	TERMINATION. Either party may terminate this Agreement at
anytime with or without cause by giving thirty (30) days written notice to the other party. The Consultant cannot be terminated
within the first thirty (30) days, however notice can be given during this term. Should the Consultant default in the performance
of this Agreement or materially breach any of its provisions, the Company may, in its sole discretion, terminate this Agreement
immediately upon written notice to the Consultant.

 

		7.	NO THIRD PARTY RIGHTS. The parties warrant and represent that
they are authorized to enter into this Agreement and that no third parties, other than the parties hereto, have any interest in
any of the services or the Warrant contemplated hereby.

 

		8.	ABSENCE OF WARRANTIES AND REPRESENTATIONS. Each party hereto acknowledges that they have
signed this Agreement without having relied upon or being induced by any agreement, warranty or representation of fact or opinion
of any person not expressly set forth herein. All representations and warranties of either party contained herein shall survive
its signing and delivery.

 

		9.	GOVERNING LAW. This Agreement shall be governed
by and construed in accordance with the law of the State of New York.

		 	 

		10.	ATTORNEY'S FEES. In the event of any controversy,
claim or dispute between the parties hereto, arising out of or in any manner relating to this Agreement, including an attempt
to rescind or set aside, the prevailing party in any action brought to settle such controversy, claim or dispute shall be entitled
to recover reasonable attorney's fees and costs.

		 	 

		11.	ARBITRATION. Any controversy between the parties
regarding the construction or application of this Agreement, any claim arising out of this Agreement or its breach, shall be submitted
to arbitration in Nassau County, NY before one arbitrator in accordance with the Commercial Arbitration Rules of the American
Arbitration Association, upon the written request of one party after service of that request on the other party. The cost of arbitration
shall be borne by the losing party. The arbitrator is also authorized to award attorney's fees to the prevailing party.

		 	 

		12.	VALIDITY.
If any paragraph, sentence, term or provision hereof shall be held to be invalid or unenforceable
for any reason, such invalidity or unenforceability shall not affect the validity enforceability of any other paragraph, sentence,
term and provision hereof. To the extent required, any paragraph, sentence, term or provision of this Agreement may be modified
by the parties hereto by written amendment to preserve its validity.

		 	 

		13.	ON-DISCLOSURE OF TERMS. The terms of this Agreement
shall be kept confidential, and no party, representative, attorney or family member shall reveal its contents to any third party
except as required by law or as necessary to comply with law or preexisting contractual commitments.

 

		14.	ENTIRE AGREEMENT. This Agreement contains the entire understanding of the parties and cannot
be altered or amended except by an amendment duly executed by all parties hereto. This Agreement shall be binding upon and inure
to the benefit of the successors, assigns and personal representatives of the parties.

 

[Signature Page Follows]

 

    	5

    	 

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Consulting Agreement effective as of the date first written above.

 

	 	 	 
	Chris Amandola	 	Name:___________________
	President	 	Title:___________________
	Millennium Medical Devices LLC	 	MedMart
	 	 	Tax ID: 46-1625558

 

    	6

    	 

    

 

EXHIBIT A

 

DESCRIPTION OF CONSULTING SERVICES

 

The Consultant agrees, to the extent reasonably
required in the conduct of its business with the Company, to place at the disposal of the Company its judgment and experience and
to provide business development services to the Company including, but not limited, to, the following:

 

		·	Providing business development, enhancement and evaluation of medical devices and services

		·	Schedule presentations, meetings and networking engagements, introductions and opportunities throughout the medical industry
and community

		·	Provide guided support in product growth and development initiatives

		·	Provide immediate direct and/or indirect adequate financing and funding for product inventory and
launches. No fees or compensation will be due unless this is provided specifically for each product accepted. There will be no
exceptions.

		·	Provide proposals for initial four products introduced for acceptance by the Company

 

CDx Diagnostics – Oral CDx

 

The patented and proprietary Oral Swab diagnostic platform consists
of a unique tissue sampling method combined with computer-assisted laboratory tissue analysis which can identify precancerous epithelial
cells that cannot be practically found by any other means. The Oral Swab provides the physician or dentist with its patented tissue
sampling instruments that are used to painlessly and non-invasively obtain complete tissue samples from the epithelium of the mouth
and throat in order to test for the presence of precancerous changes. The Oral Swab brush biopsy instrument for testing of the
mouth is handheld.

 

All necessary FDA, EU and other regulatory approvals required
to launch the Oral Swab product worldwide have already been obtained. Oral Swab testing provides life-saving potential benefits
to the patient without increasing health-care costs. All Oral Swab laboratory tissue analysis procedures are reimbursed under existing,
long-standing laboratory procedure billing codes and fee schedules, and, as such, are considered a covered benefit by virtually
all government and private medical insurance.

 

Research and review (selection process) of the products,
goods, and/or services provided by CDx that may be distributed by Millennium.

 

Research and review CDx distribution network, all
facilities to include their distribution centers, warehouses, logistic companies, freight forwarders and manufacturers/vendors
to ensure they comply with Millennium’s standards.

 

Negotiate terms and conditions along with
distribution rights and exclusivity in the US.

 

    	7

    	 

    

 

Negotiate price and cost of units for each
of Millenniums facilities

 

Negotiate volume discounts, margins, along
with cost of goods.

 

Negotiate purchase and sales minimums and
requirements.

 

Provide immediate adequate financing and funding for
product inventory and launches. No fees or compensation will be due unless this is provided specifically for each product accepted.
There will be no exceptions.

 

Atossa Genetics – ForeCYTE

 

The ForeCYTE Breast Health Test provides a cytopathological
approach for identifying breast cancer risk:

 

• Nipple
Aspirate Fluid (NAF) collected with FDA-cleared, patented MASCT® non-invasive biopsy instrument

 

• Patented
Lab Development Test (LDT) uses five biomarkers of hyperplasia and an additional marker of sample integrity to help evaluate NAF

 

• 99%
of samples sent to the laboratory provide clinically useful results

 

• Rule
out atypical hyperplasia at the gynecological visit

 

• Simple
to collect using a non-invasive breast pump biospy device

 

Provide immediate adequate financing and funding for
product inventory and launches. No fees or compensation will be due unless this is provided specifically for each product accepted.
There will be no exceptions.

 

The ForeCYTE Breast Health Test provides women ages 18-73 objective
and personalized information to improve their breast health, using a cellular diagnostic risk assessment tool. The
ForeCYTE Breast Health Test uses no radiation and helps define the biology of breast cancer and hyperplasia.

 

Research and review (selection process) of the products,
goods, and/or services provided by Atossa that may be distributed by Millennium.

 

Research and review Atossa distribution network, all
facilities to include their distribution centers, warehouses, logistic companies, freight forwarders and manufacturers/vendors
to ensure they comply with Millennium’s standards.

 

    	8

    	 

    

 

Negotiate terms and conditions along with
distribution rights and exclusivity in the US.

 

Negotiate price and cost of units for each
of Millenniums facilities

 

Negotiate volume discounts, margins, along
with cost of goods.

 

Negotiate purchase and sales minimums and
requirements.

 

Provide immediate adequate financing and funding for
product inventory and launches. No fees or compensation will be due unless this is provided specifically for each product accepted.
There will be no exceptions.

 

Heart Smart - VasoScan

 

VasoScan is designed to analyze the Autonomic Nervous System
(ANS) function, Stress and Peripheral Blood Circulation. It provides objective data to help assess disorders such as depression,
anxiety, sleep disorders, poor concentration, mental/physical stress degree, chronic fatigue and blood circulation.

 

The VasoScan product provides; early detection of arterial wall
elasticity and determination of biological arterial age in less than 5 minutes, easy to use, non-operator dependent software, monitors
effectiveness of therapeutic intervention, monitors arterial wall response to lifestyle changes / reduction of cardiovascular risk
factors, non-invasive – uses a LED/Photodiode finger probe sensor, FDA cleared, light weight and portable (1.5 lbs), user
friendly, color printout data sheet and affordable pricing.

 

Research and review (selection process) of the products,
goods, and/or services provided/distributed by Heart Samrt that may be distributed by Millennium.

 

Research and review Heart Samrt distribution network,
all facilities to include their distribution centers, warehouses, logistic companies, freight forwarders and manufacturers/vendors
to ensure they comply with Millennium’s standards.

 

Negotiate terms and conditions along with
distribution rights and exclusivity in the US.

 

Negotiate price and cost of units for each
of Millenniums facilities

 

Negotiate volume discounts, margins, along
with cost of goods.

 

Negotiate purchase and sales minimums and
requirements.

 

    	9

    	 

    

 

Provide immediate adequate financing and funding for
product inventory and launches. No fees or compensation will be due unless this is provided specifically for each product accepted.
There will be no exceptions.

 

Soteria Medical - Soterogram

 

Soterogram TM, is a non-invasive patented and FDA approved
device that aids and assists in the prediction and detection of arteriosclerosis and cardio vascular disease.

 

Three separate, disposable blood pressure cuffs, one for the
upper arm, one for the inner thigh and one for the ankle are mounted on the patient. These separate and distinct blood pressure
cuffs will obtain arterial readings as part of the Soterogram procedure.

 

The company’s proprietory software then will track and
process unique identifying serial numbers that will be assigned to each and every cuff.

 

The entire Soterogram process, including the patented cuffs
and proprietary software, will help the healthcare professional predict arteriosclerosis and cardio vascular disease thereby enabling
preventative and/or early detection courses of treatment maximizing patient outcome.

 

Negotiate terms and conditions along with
distribution rights and exclusivity in the US.

 

Negotiate price and cost of units for each
of Millenniums facilities

 

Negotiate volume discounts, margins, along
with cost of goods.

 

Negotiate purchase and sales minimums and
requirements.

 

Provide immediate adequate financing and funding for
product inventory and launches. No fees or compensation will be due unless this is provided specifically for each product accepted.
There will be no exceptions.

 

    	10

    	 

    

 

EXHIBIT B

 

PRODUCT PROPOSAL FORM

(SAMPLE)

 

	Organization:	 	 
	 	 	 
	Product: 	 	 
	 	 	 
	Producer: 	 	 

 

Description: 

	 
	 
	 
	 
	 
	 

 

We believe the aforementioned product is a viable product that
could prove to be a very successful and profitable product for Millennium to be associated with. As such, we submit this proposal
for your acceptance to pursue a formal agreement to distribute this product.

 

Organization

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

The proposed product is accepted. Upon
fulfillment of the terms, conditions and requirements of the Consulting Agreement dated January 23rd, 2013 by and between
the Organization and Millennium Medical Devices LLC, [*].

 

Agreed and Accepted:

 

Millennium Medical Devices LLC

 

	________________________________	_______________
	By:_____________________________	Date

 

The proposed product is NOT accepted. Millennium
respectfully declines this product proposal and elects to have no further involvement with such product and shall have no commitments
or liabilities whatsoever related to this product

 

    	11

    	 

    

 

Respectfully Declined:

 

Millennium Medical Devices LLC

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

PRODUCT PROPOSAL FORM

 

    	12

    	 

    

 

Organization:MedMart

 

Product: CDx Oral Biopsy Brush

 

Producer: CDx Diagnostics Inc.

 

Description: The
patented and proprietary Oral Swab diagnostic platform consists of a unique tissue sampling method combined with computer-assisted
laboratory tissue analysis which can identify precancerous epithelial cells that cannot be practically found by any other means.
The Oral Swab provides the physician or dentist with its patented tissue sampling instruments that are used to painlessly and non-invasively
obtain complete tissue samples from the epithelium of the mouth and throat in order to test for the presence of precancerous changes.
The Oral Swab brush biopsy instrument for testing of the mouth is handheld.

 

All necessary FDA, EU and other regulatory approvals required
to launch the Oral Swab product worldwide have already been obtained. Oral Swab testing provides life-saving potential benefits
to the patient without increasing health-care costs. All Oral Swab laboratory tissue analysis procedures are reimbursed under existing,
long-standing laboratory procedure billing codes and fee schedules, and, as such, are considered a covered benefit by virtually
all government and private medical insurance.

 

We believe the aforementioned product is a viable product that
could prove to be a very successful and profitable product for Millennium to be associated with. As such, we submit this proposal
for your acceptance to pursue a formal agreement to distribute this product.

 

Organization

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

The proposed product is accepted. Upon
fulfillment of the terms, conditions and requirements of the Consulting Agreement dated January 23rd, 2013 by and between
the Organization and Millennium Medical Devices LLC, [*].

 

Agreed and Accepted:

 

Millennium Medical Devices LLC

 

	________________________________	_______________
	By:_____________________________	Date

 

    	13

    	 

    

 

The proposed product is NOT accepted. Millennium
respectfully declines this product proposal and elects to have no further involvement with such product and shall have no commitments
or liabilities whatsoever related to this product

 

Respectfully Declined:

 

Millennium Medical Devices LLC

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

PRODUCT PROPOSAL FORM

 

    	14

    	 

    

 

Organization:MedMart

 

Product: ForeCyte Breast Health
Test

 

Producer: Atossa Genetics Inc.

 

Description: The
ForeCYTE Breast Health Test provides a cytopathological approach for identifying breast cancer risk:

 

• Nipple
Aspirate Fluid (NAF) collected with FDA-cleared, patented MASCT® non-invasive biopsy instrument

 

• Patented
Lab Development Test (LDT) uses five biomarkers of hyperplasia and an additional marker of sample integrity to help evaluate NAF

 

• 99%
of samples sent to the laboratory provide clinically useful results

 

• Rule
out atypical hyperplasia at the gynecological visit

 

• Simple
to collect using a non-invasive breast pump biospy device

 

The ForeCYTE Breast Health Test provides women ages 18-73 objective
and personalized information to improve their breast health, using a cellular diagnostic risk assessment tool. The
ForeCYTE Breast Health Test uses no radiation and helps define the biology of breast cancer and hyperplasia.

 

We believe the aforementioned product is a viable product that
could prove to be a very successful and profitable product for Millennium to be associated with. As such, we submit this proposal
for your acceptance to pursue a formal agreement to distribute this product.

 

Organization

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

The proposed product is accepted. Upon
fulfillment of the terms, conditions and requirements of the Consulting Agreement dated January 23rd, 2013 by and between
the Organization and Millennium Medical Devices LLC, [*].

 

    	15

    	 

    

 

Agreed and Accepted:

 

Millennium Medical Devices LLC

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

The proposed product is NOT accepted. Millennium
respectfully declines this product proposal and elects to have no further involvement with such product and shall have no commitments
or liabilities whatsoever related to this product

 

Respectfully Declined:

 

Millennium Medical Devices LLC

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

PRODUCT PROPOSAL FORM

 

    	16

    	 

    

 

Organization:MedMart

 

Product: VasoScan

 

Producer: VasoScan through Heart
Smart

 

Description: VasoScan
is designed to analyze the Autonomic Nervous System (ANS) function, Stress and Peripheral Blood Circulation. It provides objective
data to help assess disorders such as depression, anxiety, sleep disorders, poor concentration, mental/physical stress degree,
chronic fatigue and blood circulation.

 

The VasoScan product provides; early detection of arterial wall
elasticity and determination of biological arterial age in less than 5 minutes, easy to use, non-operator dependent software, monitors
effectiveness of therapeutic intervention, monitors arterial wall response to lifestyle changes / reduction of cardiovascular risk
factors, non-invasive – uses a LED/Photodiode finger probe sensor, FDA cleared, light weight and portable (1.5 lbs), user
friendly, color printout data sheet and affordable pricing.

 

We believe the aforementioned product is a viable product that
could prove to be a very successful and profitable product for Millennium to be associated with. As such, we submit this proposal
for your acceptance to pursue a formal agreement to distribute this product.

 

Organization

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

The proposed product is accepted. Upon
fulfillment of the terms, conditions and requirements of the Consulting Agreement dated January 23rd, 2013 by and between
the Organization and Millennium Medical Devices LLC, [*].

 

Agreed and Accepted:

 

Millennium Medical Devices LLC

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

    	17

    	 

    

 

The proposed product is NOT accepted. Millennium
respectfully declines this product proposal and elects to have no further involvement with such product and shall have no commitments
or liabilities whatsoever related to this product

 

Respectfully Declined:

 

Millennium Medical Devices LLC

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

PRODUCT PROPOSAL FORM

 

    	18

    	 

    

 

Organization:MedMart

 

Product: Soterogram

 

Producer: Soteria Medical LLC

 

Description: Soterogram
TM, is a non-invasive patented and FDA approved device that aids and assists in the prediction and detection of arteriosclerosis
and cardio vascular disease.

 

Three separate, disposable blood pressure cuffs, one for the
upper arm, one for the inner thigh and one for the ankle are mounted on the patient. These separate and distinct blood pressure
cuffs will obtain arterial readings as part of the Soterogram procedure.

 

The company’s proprietory software then will track and
process unique identifying serial numbers that will be assigned to each and every cuff.

 

The entire Soterogram process, including the patented cuffs
and proprietary software, will help the healthcare professional predict arteriosclerosis and cardio vascular disease thereby enabling
preventative and/or early detection courses of treatment maximizing patient outcome.

 

We believe the aforementioned product is a viable product that
could prove to be a very successful and profitable product for Millennium to be associated with. As such, we submit this proposal
for your acceptance to pursue a formal agreement to distribute this product.

 

Organization

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

The proposed product is not accepted. Upon
fulfillment of the terms, conditions and requirements of the Consulting Agreement dated January 23rd, 2013 by and between
the Organization and Millennium Medical Devices LLC, [*].

 

Agreed and Accepted:

 

Millennium Medical Devices LLC

 

	________________________________	_______________
	By:_____________________________	Date

 

    	19

    	 

    

 

The proposed product is NOT accepted. Millennium
respectfully declines this product proposal and elects to have no further involvement with such product and shall have no commitments
or liabilities whatsoever related to this product

 

Respectfully Declined:

 

Millennium Medical Devices LLC

 

	________________________________	_______________
	 	 
	By:_____________________________	Date

 

    	20Exhibit 10.1

 

 

 

[MEDGENICS LETTERHEAD]

 

 

 

November 27, 2013

 

 

 

Mr. Marvin Garovoy

Dear Marvin:

 

Reference is made
to that certain Employment Agreement dated July 8, 2012 between Medgenics, Inc., a Delaware corporation (the “Company”),
and you (the “Employment Agreement”). Pursuant to Section 6.1 of the Employment Agreement, the Company hereby
exercises it right to terminate the Employment Agreement effective December 31, 2013 (the “Effective Date”)
and this letter shall constitute the advance written notice required thereunder. As provided in Section 6.4 of the Employment Agreement,
the Company shall pay to you on the Effective Date an amount equal to all wages and benefits owing to you through the Effective
Date. As provided in Section 6.5 of the Employment Agreement, the Company shall continue to pay salary (as defined in the Employment
Agreement) to you for the period commencing on January 1, 2014 and ending on June 30, 2014.

 

As set forth in the
Employment Agreement and in consideration for the benefits provided to you by the Company pursuant to the following paragraph,
you reconfirm your agreement to faithfully and fully honor the terms and conditions of Sections 7, 8 and 9 of the Employment Agreement
regarding the obligations of confidentiality, non-solicitation, disclosure and assignment of inventions, which shall continue as
provided in the Employment Agreement and according to all applicable laws, notwithstanding the termination of the Employment Agreement
and the termination of your employment with the Company.

 

In consideration for
your signing and delivering a General Release and Waiver on the Effective Date in the form attached hereto as Exhibit A,
the Company shall cause (i) you to become fully vested as of the Effective Date in all unvested outstanding stock options under
the grant originally made to you on July 1, 2011, and (ii) all outstanding options which are vested as of the Effective Date to
continue to be exercisable through December 31, 2014 and otherwise in accordance with the terms of the Medgenics, Inc. Stock Incentive
Plan and applicable award documents.

 

    	 

    	 

    

You further acknowledge
receipt of the Notice to Employee as to Change in Relationship issued pursuant to Section 1089 of the California Unemployment Insurance
Code, a copy of which is attached hereto as Exhibit B. You also acknowledge that you have received from the Company a copy
of the “California’s Programs for the Unemployed” published by the Employment Development Department of the State
of California.

 

	 	Sincerely,
	 	 	 
	 	MEDGENICS, INC.
	 	 	 
	 	By:	 	/s/ John Leaman	 
	 	Name:	John Leaman
	 	Title:	Chief Financial Officer

 

 

 

By signing this letter,
I acknowledge and I have had the opportunity to review this letter carefully with an attorney of my choice; that I have read this
letter and understand its terms; and that I voluntarily agree to all of the terms and conditions of this letter.

 

Dated: November 27, 2013

	 	/s/ Marvin Garovoy	 
	 	Marvin Garovoy

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]